HPV vaccine i USA
GSK pulls HPV vaccine from US market as take-up rates HPV is a failing vaccine. With take-up rates falling, drug giant GlaxoSmithKline
from the US market, and America’s health regulators, the Centers introduced a two-dose schedule for the one remaining HPV vaccine, cancer.
GSK shipped its final batch of Cervarix at the end of August, and has announced market demand.” The vaccine generated just £3m of revenues in the US for When the two vaccines were launched, drug industry analysts were forecasting annual dampened the take-up among teenage girls, and they have achieved just a 40 per cent The CDC is increasing the dosage that must be given from one shot to two, after a director Tom Frieden immediately sanctioned the suggestion. The move is being supported parents to have their teenage daughters vaccinated.